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The capsid of canine parvovirus (CPV) was assayed for susceptibility to proteases and for structural variation. The natural
cleavage of VP2 to VP3 in CPV full (DNA containing) particles recovered from tissue culture occurred within the sequence
Arg-Asn-Glu-Arg2Ala-Thr. Trypsin, chymotrypsin, bromelain, and cathepsin B all cleaved .90% of the VP2 to VP3 in full but
not in empty capsids and did not digest the capsid further. Digestion with proteinase K, Pronase, papain, or subtilisin cleaved
the VP2 to VP3 and also cleaved at additional internal sites, causing particle disintegration and protein degradation. Several
partial digestion products produced by proteinase K or subtilisin were ;31–32.5 kDa, indicating cleavage within loop 3 of the
capsid protein as well as other sites. Protease treatment of capsids at pH 5.5 or 7.5 did not significantly alter their
susceptibility to digestion. The isoelectric point of CPV empty capsids was pH 5.3, and full capsids were 0.3 pH more acidic,
but after proteolysis of VP2 to VP3, the pI of the full capsids became the same as that of the empty capsids. Antibodies
against various capsid protein sequences showed the amino termini of most VP2 molecules were on the outside of full but
not empty particles, that the VP1-unique sequence was internal, and that the capsid could be disintegrated by heat or urea
treatment to expose the internal sequences. Capsids added to cells were localized within the cell cytoplasm in vesicles that
appeared to be lysosomes. Microinjected capsids remained primarily in the cytoplasm, although a small proportion was
observed to be in the nucleus after 2 h. After CPV capsids labeled with [35S]methionine were bound to cells at 0°C and the
cells warmed, little cleavage of VP1 or VP2 was observed even after prolonged incubation. Inoculation of cells with virus in
the presence of proteinase inhibitors did not significantly reduce the infection. © 1998 Academic Press
INTRODUCTION
Viral capsids protect the viral genome during spread
between hosts and cells, and they also deliver the
infectious nucleic acid and other necessary compo-
nents into the cell. During the process of cell entry,
specific conformational changes of the viral structural
proteins must occur to allow the capsid, nucleocapsid,
or nucleic acid to be carried from outside the cell into
the cytoplasm and, if necessary, to the nucleus (Marsh
and Helenius, 1989). During that process, the capsid
must also specifically release the viral nucleic acid or
nucleoprotein in the correct form and cellular compart-
ment for replication.
Many viruses undergo specific activation or matura-
tion changes after virus assembly that make the virion
infection competent. Those changes may prevent the
newly synthesized proteins or virus from undergoing
conformational changes during vesicular transport, or
they may prevent it from reinfecting the same cell. In
many cases, this virion maturation process involves di-
gestion of virion proteins by viral or cellular proteases
(Cotten and Weber, 1995; Greber et al., 1996; Lu et al.,
1996; Sturzenbecker et al., 1987; Virgin et al., 1994). The
viral proteins or capsids may then undergo further struc-
tural transitions induced by cell receptor binding or by
exposure to low pH during endocytosis (Greber, 1993;
Lee et al., 1993; Marsh and Helenius, 1989; Prchla et al.,
1994; Varga et al., 1991).
The infection process of most enveloped viruses involves
viral proteins fusing the viral envelope with the plasma
membrane at the cell surface or within endosomes. For
many viruses, the envelope proteins undergo dramatic
structural changes in the endosome under the influence of
low pH, and those changes make them fusion competent
(Doms, 1993a, 1993b). Some well-described examples in-
clude influenza virus hemagglutinin, Semliki Forest virus
envelope protein, and tick-borne encephalitis virus enve-
lope protein (Bullough et al., 1994; Fuller et al., 1995; Lobigs
and Garoff, 1990; Stiasny et al., 1996).
For most nonenveloped viruses, the uptake and infec-
tion pathways are less clearly understood. However,
there must also be membrane permeabilization or pen-
etration by the particle, resulting in many cases from
specific changes in the folding of structural proteins or in
some cases from exposure of myristoylated compo-
nents, as seen for reoviruses, adenoviruses, and picor-
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naviruses (Dryden et al., 1993; Fricks and Hogle, 1990;
Sahli et al., 1993; Sturzenbecker et al., 1987).
Parvoviruses have a stable 25-nm nonenveloped spher-
ical capsid containing a single-stranded DNA (ssDNA) ge-
nome of ;5000 nucleotides (Chapman and Rossmann,
1993; Cotmore and Tattersall, 1987; Tsao et al., 1991). Dif-
ferent autonomous parvoviruses infect vertebrate and in-
vertebrate animals, and most have relatively narrow host
ranges. The host ranges of CPV, minute virus of mice
(MVM), Aleutian mink disease virus (ADV), and porcine
parvovirus are controlled, at least in part, by specific se-
quences within their capsid protein genes (Ball-Goodrich et
al., 1991, 1992; Bergeron et al., 1996; Bloom et al., 1993;
Chang et al., 1992). Infection of cells by CPV most likely
involves an endocytic pathway, and infection can be
blocked by cell treatments that raise the endosomal pH or
block endosomal trafficking (Basak and Turner, 1992; Vihi-
nen-Ranta et al., 1998). However, it is not known how the
stable capsid penetrates the cellular or endosomal mem-
branes, whether the capsid requires specific activation for
infection, how it is transported within the cytoplasm, and
where in the infectious pathway the DNA is released so it
can eventually replicate in the nucleus.
The structures of CPV full (DNA-containing) and empty
capsids, FPV empty capsids, MVM full and empty cap-
sids, and empty virus-like particles of human parvovirus
B19 have been determined using x-ray crystallography
(Agbandje et al., 1994, 1993; Llamas-Saiz et al., 1997;
Tsao et al., 1991). The CPV and FPV capsids are T 5 1
icosahedrons assembled from 60 copies of a combina-
tion of ;10% of the 82-kDa VP1 and 90% of the 67-kDa
VP2 (Tsao et al., 1991; Paradiso, 1982). VP1 contains the
entire sequence of VP2 and an additional 143 amino-
terminal residues. In full capsids, VP2 may be cleaved
near the amino terminus by host proteases to form VP3,
and in MVM, H1 or CPV capsids that cleavage can be
mimicked by trypsin treatment (Clinton and Hayashi,
1975, 1976; Paradiso et al., 1982, 1984; Tattersall, 1977;
Tattersall et al., 1976; Tullis et al., 1992). Amino-terminal
sequencing showed that trypsin cleaved the VP2 of H1
virus full capsids after VP2 arginine-21, within the se-
quence 16Asn-Ala-Arg-Val-Glu-Arg2Ser22 (Paradiso et
al., 1984), although in one study, the natural cleavage site
could not be clearly identified by sequencing the VP3
from MVM (Tullis et al., 1992). Mutation or removal of the
18Arg-Val-Glu-Arg21 sequence in MVM did not prevent
processing of VP2 to VP3-like forms, indicating that pro-
teases can cleave the amino-terminal sequence at vari-
ous positions in the exposed sequences (Tullis et al.,
1992). However, those mutants were somewhat deficient
in cell infection and plaquing. The proteins in ADV cap-
sids in vivo were found to be largely cleaved into a
number of fragments, presumably by host proteases
(Aasted et al., 1984).
In the atomic structures of the full and empty CPV and
empty FPV capsids, VP1 and VP2 were only resolved
from VP2 residue 37, and the structures and locations of
the amino termini of VP1, VP2, or VP3 were not seen
FIG. 1. Proteinase susceptibility of CPV capsids. (A) Sucrose gradient purified CPV full or empty capsids incubated with the proteinases indicated
for 20 or 60 min at pH 7 or 5.5 and then eletrophoresed in 7.5% polyacrylamide gels. Gels were stained with Coomassie Blue. (B) Incubation of CPV
full capsids with cathepsin B or cathepsin D for 1 h at pH 5.5 or 4.5 and then electrophoresis as in (A). E, Empty capsids; F, full capsids.
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(Agbandje et al., 1993; Tsao et al., 1991; Wu and Ross-
mann, 1993). Protease susceptibility indicates that some
of the VP2 amino-terminal sequences are outside the full
capsid, as does the fact that antibodies against VP2
amino-terminal peptides neutralize the virus (Casal et al.,
1995; Langeveld et al., 1994). A pore was seen within the
icosahedral five-fold axes of the full and empty capsids,
and it contained electron density in full capsids that is
presumed to be sequences near the VP2 amino terminus
(Tsao et al., 1991). At least one pore per capsid most
likely contains DNA in that MVM and AAV full capsids
have the 59 end of the viral DNA outside the particle and
attached to the NS1 or Rep protein, respectively (Cot-
more and Tattersall, 1989; Prasad and Trempe, 1995).
The five-fold pore appears to be of sufficient size to allow
only one polypeptide chain to pass to the outside of the
capsid, and the conservation of a sequence of glycines
and serines between VP2 residues 26 and 40 was sug-
gested to be due to the need for a narrow diameter and
unstructured polypeptide sequence within the pore (Tsao
et al., 1991; Tullis et al., 1992; Xie and Chapman, 1996).
The CPV and FPV capsids are relatively rigid structures,
with the main areas of structural flexibility being ob-
served in the cylinder surrounding the five-fold axis (VP2
residues 154–163) and in a partially surface-exposed
loop made up of VP2 residues 360–372 (Wu and Ross-
mann, 1993; Xie and Chapman, 1996).
CPV and FPV are members of the feline subgroup of
the autonomous parvoviruses and are .99% identical in
DNA sequence, but they differ antigenically and in feline
and canine host range (Parrish, 1990, 1994; Truyen et al.,
1996, 1995). Sequences controlling canine host range
map to at least three regions of the capsid protein gene,
and VP2 residues 93 (Lys in FPV, Asn in CPV) and 323
(Asp in FPV, Asn in CPV) and the region around VP2
residue 300 all play roles (Chang et al., 1992; Horiuchi et
al., 1994; Parker and Parrish, 1997). In animals, CPV and
FPV infect cells of the lymphoid tissues and the intestinal
epithelium, and the virions pass through the intestinal
lumen and are shed in the feces, remaining infectious in
the environment for weeks or months.
The restrictions in viral host ranges occur at a stage in
the infection pathway between virus binding to the cell
surface and DNA replication (Horiuchi et al., 1992; Parker
and Parrish, 1997). However, the stages in infection that
might influence the viral host ranges are poorly under-
stood, and little is known about the role of the capsid
structures or its variation in this process. Empty and full
capsids differ in the presence of symmetrically arranged
ssDNA in full particles and some associated differences
in the protein structures near the DNA (Chapman and
Rossmann, 1995; Tsao et al., 1991; Xie and Chapman,
1996). The amino terminus of VP2 can be removed by
proteolysis of full capsids with little effect on virus infec-
tivity, and any function of that peptide exposure or cleav-
age is not understood (Tsao et al., 1991; Tullis et al.,
1992). Two forms of the MVM and H1 full capsids have
been defined in which newly synthesized capsids have
densities of 1.47 g/cm3 in CsCl gradients, and after pro-
longed incubation in culture, those band at ;1.42 g/cm3.
The cause of that density conversion is unknown, but it is
not directly related to the VP2-to-VP3 cleavage (Clinton
and Hayashi, 1975, 1976; Paradiso, 1981).
To further examine the capsid structure and to further
define capsid functions that may play roles in cell infec-
tion, we examined the CPV capsid structure using pro-
tease treatments and specific antibody probes. Variation
in the capsid charge was also determined, as was the
exposure of the VP2 amino terminus and other se-
quences. The processing and transport of the capsids
and their proteins within cells were examined by natural
infection or microinjection. The capsids proved to be very
stable and structurally invariant in most of the assays
used, and any functions involved in cell infection must be
very subtle or only observed in association with cellular
molecules.
RESULTS
Protease treatments
Incubation of purified parvovirus capsids with pro-
teases that represent a variety of cleavage specificities
at pH 7.0 or 5.5 resulted in two types of cleavage: con-
FIG. 2. Limited proteinase digestion of full virus capsids. Purified
capsids were incubated with proteinase K or subtilisin at 37°C for 0, 5,
20, 60, or 90 min, and then tubes were placed immediately into boiling
water. Proteins were separated by 10% PAGE and transferred to nitro-
cellulose membranes, and the blots were probed with antibodies
against SDS-denatured CPV capsids or with mouse monoclonal anti-
peptide 362–373. The bound antibodies were detected with anti-spe-
cies IgG–HRPO and SuperSignal and exposed to x-ray film. Molecular
weight standards (MW) are given in kDa.
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version of VP2 to VP3 and particle degradation. The full
virus preparations used contained approximately equal
amounts of VP2 and VP3, and most proteases tested
rapidly converted .90% of the remaining VP2 to VP3 (Fig.
1). No reduction in VP1 was consistently observed until
the VP3 was degraded, when amounts of VP1 were
reduced in parallel. Essentially no cleavage of VP2 to
VP3 was observed in empty virus capsids (Fig. 1A).
Cathepsins B and D were tested in similar assays at pH
5.5 and 4.5, and although those enzymes rapidly di-
gested control proteins or virus heated to 100°C, neither
digested VP2 to VP3 in capsids at pH 5.5. At pH 4.5, only
cathepsin B digested the VP2 to VP3 (Fig. 1B).
Virus heated to 100°C for 2 min before the proteinase
treatment was rapidly degraded by all proteinases tested
(results not shown). After incubation of full capsids with
trypsin, chymotrypsin, or bromelain, only the VP2-to-VP3
cleavage was detected. Treatment with proteinase K,
subtilisin, or papain rapidly converted VP2 in full but not
empty capsids to VP3, and then both capsids forms were
degraded (Fig. 1A). Pronase rapidly degraded both full
and empty capsids (results not shown).
To determine the cleavages that were occurring and the
cleavage products that were released, full capsids were
subjected to limited digestion with proteinase K or subtilisin
for varying times. Both proteases generated fragments of
31–35 kDa that were detected by Western blotting using
antibodies against SDS-denatured capsids (Fig. 2), and a
subset of those fragments were also detected by anti-
peptide 362–373 (Fig. 2) or anti-peptide 39–50 sera (not
shown). Several fragments of ,20 kDa were also gener-
ated that were recognized only by the anti-SDS-denatured
capsid antibodies. Those products appeared to be primarily
protease-resistant subfragments of the capsid protein. The
fact that the cleavages occurred during the incubation of
the capsid with the protease, and not during the process of
denaturation of the capsid before electrophoresis, is shown
by the 0 time result. Although the protease was included in
that reaction, none of the specific degradation products
were detected by Western blotting. A product of 31 kDa
reacting with the anti-39–50 antibody indicated that at least
one major cleavage occurred between VP2 residues 290–
310, in a region associated with control of canine host
range (Llamas-Saiz et al., 1996; Parker and Parrish, 1997).
Amino-terminal sequencing of VP3 prepared from full
virus without additional protease digestion showed the
sequence Ala-Thr-Gly-Ser-Gly, indicating that cleavage
occurred after VP2 residue 19, within the sequence
16Arg-Asn-Glu-Arg2Ala-Thr-Gly-Ser23. No other amino
acids were detected at .20% the level of the strongest
amino acid peak during the first five sequencing cycles.
The exposure of the amino terminus of VP2 was also
confirmed with various specific anti-peptide antibodies with
the specificities shown in Fig. 3. As seen in Fig. 4, antibod-
ies against VP2 peptides 3–12, 10–20, and 16–27 all recog-
nized intact full CPV capsids, and that reactivity did not
FIG. 3. Diagrammatic representation of part of the structure of the CPV capsid showing two adjacent VP2 molecules surrounding the pore at the
five-fold axis of symmetry. A linear sequence approximating the extended length of the amino-terminal 36 amino acids of VP2 is shown; after
proteolysis of VP2, the amino terminus of VP3 is at residue 20. Positions of the peptides used to prepare structure specific antibodies or the epitope
recognized by MAb A3B10 are indicated.
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increase after urea denaturation of the capsid. In contrast,
the antibodies against peptides 39–51 and 258–270 reacted
to low or undetectable levels with the intact virus capsids,
but those epitopes reacted strongly after capsids were
treated with urea of .;3 M. Monoclonal antibody (mAb)
A3B10 reacted with native capsids but not with virus that
had been heated to 100°C or treated with .6 M urea (Figs.
4 and 5). Two mAbs prepared against peptide 362–373
reacted to low levels with native CPV or FPV but reacted to
8- to 10-fold higher levels against viruses denatured with
heat or urea (Fig. 5A). Because the structure of the loop
between VP2 residues 360 and 375 may be affected by pH
and that may cause the difference in pH dependence of
hemagglutination seen between CPV and FPV (Agbandje et
al., 1993; Chang et al., 1992), those antibodies were also
incubated with capsids at pH 4.5–7.5. A significant effect on
mAb binding was seen only at pH 4.5, where the reactivity
with capsids was reduced to a greater degree than the
binding to peptide 362–373 conjugated to bovine serum
albumen (Fig. 5B).
Capsid pI
Isoelectric focusing of CPV empty capsids showed
them to have a pI of ;5.3, indicating that the particle is
negatively charged at physiological pH. The pI of the full
FIG. 4. Exposure of various virus sequences in empty or full virus capsids after either no treatment or incubation with 1.5–7 M urea. The capsids
were then spotted onto a membrane and detected with the antibodies against the VP1 unique region (VP1), against various VP2 peptides, or MAb
A3B10, which recognizes only assembled capsids. The bound antibodies were detected with anti-species IgG-HRPO and SuperSignal and exposed
to x-ray film, and the films were scanned to determine the relative binding.
FIG. 5. Reactivity in ELISA of mAb P1F6 or P5G5, which recognize peptide 362–373, a variable loop between CPV and FPV. (A) Reaction of the mAb
with either native or boiled CPV capsids from either CPV or FPV or reaction of mAb A3B10, which recognizes only intact capsids. (B) Effect of pH on
the binding of mAb P1F6 and P5G5 to CPV or FPV full and empty capsids or with peptide 362–373 conjugated to BSA. Antibodies were incubated
for 1 h with the various antigens at pH 4.5, 5.5, 6.5, and 7.5 and then washed and reacted with anti-mouse IgG HRPO and substrate in the normal
incubation and wash solutions. The optical density results were normalized to the highest optical density reading obtained for each virus–antibody
combination.
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capsid was ;0.3 pH less than that of the empty particle,
but trypsin treatment converted that full virus to a form
with the pI of the empty particle (Fig. 6).
Virus uptake and microinjection
[35S]Methionine-labeled virus was bound to the cells
at 0°C for 1 h, and then the cells were washed and
incubated at 37°C. About 80% of the cell-associated virus
was released into the supernatant after warming (Fig. 7;
results not shown). The remaining bound capsid proteins
were recovered in similar amounts over the next 24 h
(Fig. 7). Conversion of VP2 to VP3 in the full capsids was
detected only after 6- to 24-h incubation with the cells
(Fig. 7A), and trypsin treatment of the capsids used in
those studies showed that 50% of the VP2 could be
converted to VP3 (Fig. 7B).
Microscopic examination of virus uptake was followed
by incubation of cells with purified full capsids for vari-
ous times. After 2 h, native and biotinylated capsids were
detected within vesicles in the perinuclear region of the
cell (Fig. 8). Those vesicles also costained for lysosomal
glycoprotein, suggesting that the virus primarily became
localized in lysosomes (Fig. 8C), and 24 h after uptake,
the capsid antigens were still readily detected in such
vesicles (results not shown).
After microinjection of purified full CPV capsids into
the cytoplasm of A72 cells, most of the antigen remained
in the cytoplasm (Fig. 9). By 2 h, a small proportion of the
injected antigen was seen within the nucleus, as dem-
onstrated by confocal microscopy, where it was excluded
from the nucleoli (Fig. 9).
Proteinase inhibitors
Infection of cells with freshly prepared full CPV cap-
sids containing no VP3 was examined in the presence of
the proteinase inhibitors trans-epoxysuccinyl-L-leucylam-
ide(4-guanidino)-butane (E64) (100 or 400 mM), leupeptin
(100 mM), aprotinin (1 mg/ml), or pepstatin A (0.75 mM).
There was little decrease in infection titer when the
inhibitor was added 1 or 4 h before virus addition com-
pared with cultures with no inhibitor or compared with
cultures in which the inhibitor was added to the cultures
1 h after virus addition (Table 1).
DISCUSSION
A variety of approaches were taken to investigate the
structural variation and stability of the CPV capsid and its
role in cell infection. Variation in the susceptibility of viral
proteins to protease treatment and structure-specific an-
tibodies have been widely used to investigate the varia-
tion of other viruses and their proteins (Baer et al., 1997;
Bothner et al., 1998; Fricks and Hogle, 1990; Ketterlius
and Wiegers, 1994; Stiasny et al., 1996; Virgin et al., 1994).
The cleavage of the VP2 to VP3 in CPV and related
parvoviruses has been widely reported in previous stud-
ies, but the mechanisms involved and any associated
functions are not completely understood. Here we show
that the natural cleavage of VP2 to VP3 in CPV occurs
after VP2 residue 19, in the equivalent position to that
determined for trypsin-treated H1 virus (Paradiso et al.,
FIG. 7. (A) Uptake of [35S]methionine-labeled CPV full and empty
capsids into cells. The virus was bound on ice for 1 h, and then the cells
washed, and one sample was collected (0 min). The remaining cultures
were warmed to 37°C, and the cells were lysed at the times indicated.
Materials collected at each time point were electrophoresed in 10%
acrylamide gels and subjected to fluorography. (B) Control analysis of
capsids used in the uptake studies. Samples of the full or empty
capsids were left untreated or treated with trypsin and then analyzed as
described above.
FIG. 6. Isoelectric focusing of purified full or empty CPV capsids in
agarose gels. Samples of virus were either untreated or pretreated with
trypsin. pI standard markers are indicated.
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1984). The amino-terminal sequence is cleaved by en-
zymes with many different cleavage specificities (Fig. 1),
as has also been suggested by studies involving mu-
tagenesis of the RVER sequence in MVM (Tullis et al.,
1992). Analysis of CPV capsids by x-ray crystallography
shows the VP1 and VP2 structures from VP2 residue 37
to the carboxyl-terminal residue 584 (Tsao et al., 1991;
Wu and Rossmann, 1993), with the most obvious struc-
tural difference between the full and empty particles
being several DNA bases within each asymmetric unit
on the inside of the capsid (Chapman and Rossmann,
1995; Tsao et al., 1991). The capsid structures show that
the only pore where the amino termini could be exposed
to the outside was at the five-fold axis of symmetry,
although the pore seen appeared to be too small (mini-
mum diameter, 8 Å) to allow more than one chain to pass
through. About 50% of the protein in the full capsids
tested was VP2, and most proteases tested rapidly di-
gested .90% of that VP2 to VP3 (Fig. 1). The antibodies
recognizing the VP2 amino terminus also did not show
increased reactivity when the capsid was broken with
urea (Fig. 4), indicating that most of the remaining VP2
amino termini were exposed to the outside of the capsid
simultaneously. When newly synthesized capsids con-
taining ;100% VP2 were digested with trypsin, only 50%
of the VP2 converted to VP3, suggesting that only 50% of
the VP2 amino termini were exposed simultaneously
(Fig. 7B).
FIG. 8. Localization of biotinylated full CPV capsids in cells at 4 (A) and 16 (B) h after inoculation of A72 cells. In each case, the fluorescent label
shows the virus capsids, and this is shown along with a Nomarski DIC view of the calls, either separately (A) or overlaid (B). (C) Colocalization of
native CPV capsids and lysosomal glycoprotein in A72 cells after 2-h incubation of the virus with the cells.
FIG. 9. Two fields of A72 cells showing the localization of full capsids after microinjection into the cytoplasm and incubation for 2 h at 37°C and
then fixation and staining with rabbit anti-CPV capsid antibodies.
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It has been proposed that a glycine-rich sequence
between VP2 residues 22 and 37 would pass through the
pore in each five-fold cylinder, and electron density was
seen within the pore of the full capsids (Tsao et al., 1991).
The upper portions of the loops surrounding the five-fold
cylinder do not have any interloop bonds, so they can
most likely move apart. The capsid structure may there-
fore involve exposure of two VP2 amino termini through
each of 11 five-fold axes of the capsid (the 12th axis
presumably is occupied by DNA). Alternatively, one VP2
may be exposed, and after cleavage, the VP3 amino
terminus may withdraw into the particle and be replaced
by a new VP2 amino terminus that is subsequently
cleaved. It is possible that aspects of both models apply,
with one terminus being exposed at any one time, and
that after cleavage to VP3, there is a slower exchange
with some of the remaining VP2 termini, during which
process a number of large charged side chains would
need to transit the pore. That most of the full particles
had similar numbers of VP2 termini exposed was shown
by the fact that before trypsin treatment, their pI value
was fairly uniformly reduced by ;0.3 pH (Fig. 6).
The structure of the capsid was very stable at pH of
5.5–7.5, and no significant differences were seen in the
cleavages of the capsids when they were incubated with
the proteases at those pH values. The decreased cleav-
age by subtilisin and proteinase K at pH 5.5 probably
reflects lower protease activity under that condition. In
other studies, we have observed that the capsid stays
intact between ;pH 3.0 and 11.0 (W. Yuan and C. R.
Parrish, unpublished results).
The CPV capsids were also completely degraded by
proteases with several different specificities (Fig. 1), and
digestion products of 31–32.5 kDa were detected after
limited digestion with proteinase K and subtilisin (Fig. 2).
Probing with peptide-specific antibodies showed that
one fragment released early contained the sequence
VP2 39–50 and another contained the sequence 362–
373. A 32,500-kDa fragment containing residues 39–55
and derived from VP3 would be cleaved between VP2
residues 305 and 310, within an extended surface loop
that overlaps the three-fold related VP2 molecule (Tsao
et al., 1991), and residues 300–302 and 307–309 are all
highly accessible on the capsid surface (Xie and Chap-
man, 1996). Sequences on the shoulder of the three-fold
spike of the capsid are associated with the host range
for canine cells (Llamas-Saiz et al., 1996; Parker and
Parrish, 1997), although any relationships between the
protease cleavage and host range are not known.
CPV infection of cells may be blocked by treatments
that raise the endosomal pH (Basak and Turner, 1992).
Because we can demonstrate that there were no major
changes in the structure of the capsid at pH 5.5, a
possible mechanism might be that acid-dependent en-
dosomal proteases are required for infection. We there-
fore incubated capsids at pH 4.5 and 5.5 with the endo-
somal proteases cathepsin B and cathepsin D (Authier et
al., 1996; Blum et al., 1989). The full capsids were resis-
tant to cathepsin D, whereas cathepsin B cleaved the
VP2 to VP3 only at pH 4.5 and did not further cleave the
protein (Fig. 1B). We were also unable to show a role for
proteolysis in the process of cell infection when we
examined the fate of [35S]methionine-labeled virus taken
up into cells (Fig. 7) or inoculated cells with virus in the
presence of protease inhibitors (Table 1). Pepstatin A
and E64 are potent inhibitors of cathepsin D and cathep-
sin B, respectively, and inhibit those enzymes in the
endocytic pathway under the conditions used (Baer and
Dermody, 1997; Fiani et al., 1993). In both assays, full
viruses used for infection were purified after short peri-
ods and contained no detectable VP3 (Fig. 7; unpub-
lished results). When observed microscopically, CPV en-
tered cells through endocytosis and accumulated in ves-
icles that resemble lysosomes (Fig. 8), as has been
shown by others (Basak and Turner, 1992; Vihinen-Ranta
et al., 1998). The infecting virus or its DNA must escape
from the endosome into the cytoplasm during infection.
The mechanisms by which that occurs were not revealed
in these studies, but the capsid must undergo structural
changes during that process because intact capsids
microinjected into the cytoplasm of the cell are only
inefficiently transported into the nucleus (Fig. 9) (Vihinen-
Ranta et al., 1998). In previous studies examining the
uptake of H1 parvovirus purified from longer-term cul-
tures and labeled with 125I using chloramine T, degrada-
tion products of VP3 were detected only after several
hours of incubation with the cells, and no functional role
for that cleavage in cell infection was demonstrated
(Paradiso, 1981).
The unique amino-terminal domain of VP1 was clearly
inside both empty and full capsids in that it was not
cleaved by any protease before the degradation of VP2
and VP3 (Fig. 1) and it was recognized by antibodies only
TABLE 1
Effects of Proteinase Inhibitors on CPV Infection of NLFK Cells
Inhibitor
TCID50
Inhibitor
added before
Inhibitor
added after
E64 100 mM 4.7 4.8
E64 400 mM 4.5 4.49
Leupeptin 100 mM 5.27 4.45
Aprotinin 1 mg/ml 4.9 4.25
Pepstatin (0.75 mM) and E64
(400 mM) 3.76 3.96
Note. Data are given as log10 TCID50 titers. The CPV full virus (TCID50
104.8) purified from a short-term culture was added to cells either in the
presence of the inhibitor (added 1 or 4 h before inoculation) or when the
inhibitor was added 1 h after the virus. The inhibitors were then left in
the culture medium for the remaining incubation time.
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after capsids had been treated with urea (Fig. 4). This is
in contrast to results reported for the human parvovirus
B19 assembled in insect cells after baculovirus expres-
sion, where the VP1 unique region was on the outside of
particles containing VP1 and VP2. Those particles were
recognized by anti-VP1 antibodies, the antibodies neu-
tralized the virus infectivity (Anderson et al., 1995; Ka-
wase et al., 1995), and fusion of lysozyme with the amino-
terminal sequence of VP1 resulted in that enzyme being
displayed outside the capsid after baculovirus expres-
sion (Miyamura et al., 1994).
These results confirm that the parvovirus capsid is
very stable, and they also show that there is little struc-
tural variation over the physiological range of pH and
temperature. The changes that are observed, such as
the cleavage of the VP2 amino terminus or internal se-
quences or the shift in buoyant density of full virus after
prolonged incubation, have not yet been shown to play
critical roles in infection, although it is possible that
those functions are expressed only after the virus has
bound to a cell receptor or entered the cell. We are now
using further antibody and crystallographic analyses to
look for more subtle changes in the capsids that may be
important for cell infection and host range, as well as
further examining the virus–host cell interactions.
MATERIALS AND METHODS
Viruses and cells
Stocks of CPV-d strain of CPV type 2 and FPV-b strain
of FPV were prepared by transfection of infectious plas-
mid clones and propagated in Norden laboratories feline
kidney (NLFK) cells (Parrish, 1991). Canine A72 cells
were used for most of the studies of virus uptake and
infection (Binn et al., 1980). Cells were grown in a 50%
mixture of McCoy’s 5A and Liebovitz L15 with 5% fetal
bovine serum (FBS). Virus was purified from lysed cells
by precipitation with 3.5% polyethylene glycol (PEG) 8000
and 0.5 M NaCl at 4°C, pelleted through a 30% sucrose
cushion at 100,000 g for 6 h, and then banded twice in
10–40% sucrose gradients in 10 mM Tris–Cl (pH 7.5). The
virus was dialyzed against 10 mM Tris–Cl (pH 7.5) and
then stored at 4°C. For the antibody-binding studies,
virus was not PEG precipitated but instead was concen-
trated through filtration of the culture supernatant
through a 106-Da cutoff filter, followed by banding twice
in 10–30% glycerol gradients in 20 mM Tris–Cl (pH 7.5)
and 0.15 M NaCl (Tris–saline) for 5 h at 100,000 g at 20°C
followed by dialysis against Tris–saline.
Antibodies
Polyclonal rabbit sera were prepared by immuniza-
tion with either purified CPV capsids or CPV capsids
that had been boiled in SDS. The capsid regions
recognized by site-specific antibodies are shown in
Fig. 3. mAb 8 (A3B10) recognizes a conformational
epitope present only on intact CPV and FPV capsids
(Strassheim et al., 1994; Wikoff et al., 1994). Mouse
sera were prepared against peptides containing VP2
sequences along with an amino-terminal cysteine, in-
cluding peptide 16–27 (VP2 residues 16–27), peptide
39–51, peptide 258–270, and peptide 362–373. Pep-
tides were conjugated to sulfosuccinimidyl-4-[N-male-
imidomethyl]cyclohexane-1-carboxylate-activated key-
hole limpet hemocyanin (KLH) (Pierce Chemicals,
Rockford, IL). Mice were immunized once with KLH-
conjugated peptides in Freund’s complete adjuvant
and then repeatedly with the conjugate in Freund’s
incomplete adjuvant. To prepare mAbs against pep-
tide 362–373, immunized mice were injected intrave-
nously with KLH-conjugated peptide, and spleen cells
recovered 4 days later were used to prepare hybrid-
omas. Hybridomas were screened in ELISA against
boiled CPV-d capsids and BSA-conjugated peptide
362–373. Two positive hybridomas (P1F6, P5G5) were
cloned, and the mAbs were prepared as tissue culture
supernatants.
Rabbit sera against CPV amino-terminal sequences
(peptides 3–12 and 10–20) were provided by J. I. Casal
(Casal et al., 1995; Langeveld et al., 1994). A rabbit
antiserum against the entire VP1-specific region of MVM
was provided by P. Tattersall and S. Cotmore (Cotmore et
al., 1997). Antibodies diluted in 5% nonfat dried milk, 50
mM Tris–Cl (pH 7.5), and 200 mM NaCl were incubated
with virus bound on nitrocellulose filters and detected
with goat anti-mouse or anti-rabbit IgG horseradish per-
oxidase (HRPO) conjugate and SuperSignal substrate
(Pierce) and then exposed to x-ray film.
Protease treatments
Full or empty CPV capsids were diluted in 50 mM
Tris–Cl (pH 7.0) or 50 mM Na acetate (pH 5.5 or 4.5), both
with 100 mM NaCl. Most proteases were obtained from
Sigma Chemical (St. Louis, MO). Subtilisin Carlsberg (EC
3.4.21.62), bromelain (EC 3.4.22.4), papain (EC 3.4.22.2),
proteinase K (EC 3.4.21.64), trypsin (EC 3.4.21.4), a-chy-
motrypsin (EC 3.4.21.1), and Streptomyces griseus pro-
tease (Pronase) (EC 3.4.24.31) were used at amounts
equal to the capsid concentration. Cathepsin B (EC
3.4.22.1) and cathepsin D (EC 3.4.23.5) were obtained
from Calbiochem (San Diego, CA). Bromelain and papain
were activated with 14 mM 2-mercaptoethanol, and ca-
thepsin B was activated with 2 mM cysteine. SDS sample
buffer was added after 20 or 60 min at 37°C, the samples
were heated to 100°C for 5 min and separated by 7.5%
SDS–PAGE, and then proteins were stained with Coo-
massie Blue R250. To show that the enzymes were all
active against the viral proteins, control digestions were
performed on virus that had previously been heated to
100°C for 2 min.
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Partial proteolytic cleavage products were identified
by treating 12 mg of full capsids at 37°C with proteinase
K or subtilisin at virus-to-proteinase ratios of 1:1 or 1:2,
respectively. After various times up to 90 min, samples
were removed, mixed with SDS sample buffer, heated to
100°C for 5 min, and then separated by 10% SDS–PAGE
and electrophoretically transferred to nitrocellulose
membranes. Viral proteins were detected with rabbit
antiserum against SDS-denatured CPV or with mouse
anti-peptide 362–373, 258–270, or 39–51 antibodies.
Bound antibodies were detected as described above.
Amino-terminal sequence of VP3 protein
CPV full capsids purified from infected NLFK cells after
5 days of culture were heated in SDS sample buffer,
electrophoresed in 7.5% SDS–PAGE, and then electro-
phoretically transferred to PVDF membranes. After Coo-
massie Blue staining, the VP3 band was excised from the
membrane and sequenced in an Applied Biosystems
Procise protein sequencer for six cycles of Edman deg-
radation.
Isoelectric focusing of capsids
Capsids (5 mg) that were either untreated or pretreated
with 2 mg of trypsin for 60 min were isoelectric focused
in gels containing 1% w/v low-molecular-weight agarose,
5% w/v sorbitol, 10% v/v glycerol, and 2% w/v of pH 4–6
ampholytes (BioRad, Hercules, CA). Gels were focused
for 15 min each at 100 and 200 V and then for 60 min at
450 V; fixed with a mixture of 5% w/v trichloracetic acid,
30% v/v methanol, and 3.5% w/v sulfosalicylic acid;
washed with 100% ethanol; and then stained with Coo-
massie Blue.
Antibody recognition of capsid structures
Purified CPV full or empty capsids were left untreated
or treated with 1–8 M urea for 5 min and then bound to
nitrocellulose membranes in a slot blot apparatus. The
capsids were detected with anti-peptide sera or mAbs,
and the bound antibodies were detected with HRPO-
conjugated anti-species antibodies as described above.
Films were scanned, and the antibody bindings after
different treatments were compared.
The loop between VP2 residues 360–378 varies in
structure between CPV and FPV capsids (Agbandje et al.,
1993). To examine for conditions that cause variation of
that loop, mAbs P1F6 and P5G5 against peptide 362–373
were incubated with virus bound to ELISA plates. Some
virus was also pretreated at 100°C, and then the anti-
bodies were incubated with the virus in PBS at pH 7.2.
The antibodies were also incubated for 60 min with
capsids at pH 4.5–7.5, and the plates were washed and
incubated in PBS at pH 7.2 with anti-mouse HRPO anti-
bodies and then with substrate 2,29-azino-bis-(3-ethyl-
benzthiazidine-6-sulfonic acid) diammonium.
[35S]Methionine labeling and cell uptake of virus
capsids
NLFK cells were inoculated with 5 TCID50/cell of CPV-d
and incubated for 48 h. The cultures were then incubated
for 1 h with methionine-free medium, for 6 h with 0.2
mCi/ml of [35S]methionine, and then in complete growth
medium for 2 h. Cells were lysed with 1% v/v Nonidet
P-40 in 0.1 M Tris–Cl (pH 8.0) containing 1 mM pepstatin,
25 mM phenylmethylsulfonyl fluoride, and 100 mM leu-
peptin; frozen and thawed; and centrifuged for 10 min at
10,000 g, and the supernatant virus was pelleted at
100,000 g for 3 h. The virus was resuspended in 1 0mM
Tris–Cl (pH 8.0) and centrifuged in a 10–40% sucrose
gradient at 100,000 g for 6.5 h. Empty and full capsids
were pelleted at 100,000 g for 2 h and then resuspended
in Dulbecco’s modified Eagle’s medium. Labeled virus
was incubated with A72 cells on ice for 1 h; the cells
washed three times with the same medium and then
incubated for 0–24 h at 37°C in growth medium. The
cells were washed with PBS, lysed in SDS sample buffer,
scraped from the dishes, and boiled, and half of the
sample was electrophoresed in 7.5% SDS–PAGE. Gels
soaked in Amplify (Amersham, Arlington Heights, IL)
were dried and exposed to preflashed x-ray film at
270°C. In control studies, the purified virus samples
were incubated with 2 mg/ml trypsin for 30 min at 37°C
before electrophoresis as described above.
To examine the uptake of the capsids microscopically,
10 mg/ml of full capsids conjugated with NHS–biotin
were incubated with A72 cells in chamber slides for 1 h
at 37°C. The cells were washed with medium at 37°C,
incubated for various periods, fixed with acetone on ice
for 10 min, and stained with FITC–streptavidin. In other
studies, cells were incubated with 4 mg/ml concentration
of native virus on ice for 1 h and then warmed to 37°C for
10 min to 6 h. After fixation for 10 min with 2% parafor-
maldehyde in PBS, they were rinsed in PBS with 1 mg/ml
glycine and permeabilized with 0.05% Saponin. Virus
antigen was stained with rabbit anti-CPV capsids conju-
gated with either FITC or RITC, and in some cases the
cells were also stained with a mouse monoclonal anti-
lysosomal glycoprotein (Nabi et al., 1991), followed by
goat anti-mouse FITC. Cells were examined under visi-
ble light by differential interference contrast and for flu-
orescence with a BioRad MRC 600 confocal imaging
system, and 1-mm optical sections were recorded from
the midsection of the cells.
Purified full CPV capsids at a concentration of 1 mg/ml
were injected into A72 cells using essentially the proto-
col described for microinjection of SV40 capsids by
Clever et al. (1991). Briefly, the capsids were dialyzed
against a buffer of 48 mM K2HPO4, 14 mM NaH2PO4, and
4.5 mM KH2PO4 (pH 7.2) made up to 1 mg/ml, and ;2 3
10211 ml (;1000 particles) was injected into the cyto-
plasm of each cell. After 2 or 6 h at 37°C, the cells were
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fixed with 1:1 acetone and methanol at 0°C and then
incubated with rabbit anti-CPV capsid antibody and goat
anti-rabbit FITC.
Proteinase inhibitors and infection
Virus stocks containing no detectable VP3 were pre-
pared from short-term culture. NLFK cells were synchro-
nized in two stages: first by growth in isoleucine-free
medium for 30 h, and then by incubation with 12 mg/ml
aphidicolin in complete medium for 16 h. The cells were
inoculated with CPV and incubated with complete me-
dium containing 1 mM pepstatin, 100 mM leupeptin, and
10 mM E64 for 12 h. After freezing and thawing of the
cells, the virus was pelleted at 100,000 g for 3 h and then
banded onto a 10–40% sucrose gradient at 100,000 g for
6 h. Fractions containing full capsids were pooled and
used as an inoculum. NLFK cells seeded at 1 3 104/cm2
in a 96-well plate were treated with the proteinase inhib-
itors E62 (100 or 400 mM), with leupeptin (100 mM), with
aprotinin (1 mg/ml) 1 h before or 1 h after inoculation, or
with pepstatin (0.75 mM) 4 h before or 1 h after virus
inoculation. Inhibitors were left in the cultures, and the
cells were fixed after 46 h with a mixture of acetone and
methanol, incubated with rabbit-anti CPV and then with
goat anti-rabbit HRPO, and developed with amino ethyl
carbazole. TCID50 titers of the virus in the presence or
absence of the inhibitors were calculated.
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